A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00009737|
Recruitment Status : Completed
First Posted : March 17, 2004
Results First Posted : June 22, 2016
Last Update Posted : June 22, 2016
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer||Drug: 5-Fluorouracil Drug: Leucovorin Drug: Capecitabine [Xeloda]||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1987 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer|
|Study Start Date :||November 1998|
|Actual Primary Completion Date :||April 2004|
|Actual Study Completion Date :||April 2004|
Participants received capecitabine 1250 milligram per square meter (mg/m ^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
Drug: Capecitabine [Xeloda]
1250mg/m2 po bid on days 1-14 every 21 days.
Active Comparator: 5-Fluorouracil + Leucovorin
Participants received leucovorin 20 mg/m ^ 2 followed by 5-fluorouracil at 425 mg/m ^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
425mg/m2 iv daily from day 1 to day 5 every 28 days.
20mg/m2 iv daily from day 1 to day 5 every 28 days.
- Disease-free Survival [ Time Frame: Approximately 3 years ]Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).
- Relapse-Free Survival [ Time Frame: Approximately 3 years ]Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.
- Overall Survival [ Time Frame: Approximately 3 years ]Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).
- Mean Change From Baseline in Global Health Status at Week 25 [ Time Frame: Baseline (Days -7 to 1) and at Week 25 ]Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.
- Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters [ Time Frame: Up to Week 25 ]Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.
- Number of Participants With Any Adverse Events and Serious Adverse Events [ Time Frame: Up to Week 29 ]An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00009737
|Study Director:||Clinical Trials||Hoffmann-La Roche|